Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental COVID-19 drug SIR1-365 put to the test in early trial

NCT ID NCT04622332

First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This early-stage study tested a new drug called SIR1-365 in 45 hospitalized adults with severe COVID-19. The main goal was to see if the drug is safe and tolerable. Researchers also looked at whether it could reduce inflammation and help patients recover. The study was completed, but results are not yet available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Aga Khan University Hospital

    Karachi, Sindh, 74800, Pakistan

  • Baptist Medical Center

    Jackson, Mississippi, 39202, United States

  • Dow University Hospital, Ojha Karachi

    Karachi, Sindh, 74200, Pakistan

  • Hospital Civil Fray Antonio Alcalde

    Guadalajara, Jalisco, 14050, Mexico

  • Hospital Universitario "Dr. José Eleuterio González"

    Monterrey, Nuevo León, 64460, Mexico

  • Media Sur - Medica Sur Tlalpan

    Tlalpan, Mexico City, 14050, Mexico

  • OSF St. Francis Medical Center

    Peoria, Illinois, 61637, United States

  • Sindh Infectious Disease Hospital

    Karachi, Sindh, 74200, Pakistan

  • Triple O Research Institute

    West Palm Beach, Florida, 33407, United States

Conditions

Explore the condition pages connected to this study.